SCHEMBL23217069

SCHEMBL23217069

COc1ccc(Cl)c(Cl)c1C1CCNC(CO)C1

nearest known ligand 0.47

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
HTR2C P28335 12/20 0.47
HTR2A P28223 11/20 0.47
HTR2B P41595 8/20 0.47
ADRA1A P35348 2/20 0.35
CHRNB4 P30926 3/20 0.35
CHRNA3 P32297 3/20 0.35
HTR1A P08908 1/20 0.33
HTR1D P28221 1/20 0.33
HTR1B P28222 1/20 0.33
HTR1E P28566 1/20 0.33
HTR7 P34969 1/20 0.33
HTR3A P46098 1/20 0.33
HTR5A P47898 1/20 0.33
HTR6 P50406 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29844458 1.00 HTR2C (0.47) HTR2CHTR2AHTR2BADRA1ACHRNB4
SCHEMBL23217382 1.00 HTR2C (0.47) HTR2CHTR2AHTR2BADRA1ACHRNB4
SCHEMBL23216339 0.88 HTR2A (0.56) HTR2CHTR2AHTR2BADRA1AHTR1A
SCHEMBL29768478 0.88 HTR2A (0.56) HTR2CHTR2AHTR2BADRA1AHTR1A
SCHEMBL23227264 0.87 HTR2C (0.49) HTR2CHTR2AHTR2B
Hydrochloric Acid SCHEMBL23217143 0.86 HTR2C (0.50) HTR2CHTR2AHTR2B
Hydrochloric Acid SCHEMBL29845008 0.86 HTR2C (0.50) HTR2CHTR2AHTR2B
SCHEMBL29768399 0.86 HTR2A (0.43) HTR2CHTR2AHTR2BADRA1ACHRNB4
SCHEMBL23216843 0.85 HTR2A (0.45) HTR2CHTR2AHTR2BADRA1ACHRNB4
SCHEMBL23216481 0.85 HTR2A (0.43) HTR2CHTR2AHTR2BADRA1ACHRNB4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230049231-A1 ARYL HETEROBICYCLIC COMPOUNDS AS Kv1.3 POTASSIUM SHAKER CHANNEL BLOCKERS D. E. SHAW RESEARCH, LLC 2023-02-16 US disclosed
US-20230049231-A1 ARYL HETEROBICYCLIC COMPOUNDS AS Kv1.3 POTASSIUM SHAKER CHANNEL BLOCKERS D. E. SHAW RESEARCH, LLC 2023-02-16 US disclosed
EP-4041405-A1 ARYL HETEROBICYCLIC COMPOUNDS AS KV1.3 POTASSIUM SHAKER CHANNEL BLOCKERS D.E. Shaw Research, LLC (US) 2022-08-17 EP disclosed
WO-2021071832-A1 ARYL HETEROBICYCLIC COMPOUNDS AS KV1.3 POTASSIUM SHAKER CHANNEL BLOCKERS D.E. SHAW RESEARCH, LLC (US) 2021-04-15 WO disclosed
WO-2021071832-A1 ARYL HETEROBICYCLIC COMPOUNDS AS KV1.3 POTASSIUM SHAKER CHANNEL BLOCKERS D.E. SHAW RESEARCH, LLC (US) 2021-04-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230049231-A1 ARYL HETEROBICYCLIC COMPOUNDS AS Kv1.3 POTASSIUM SHAKER CHANNEL BLOCKERS KCNB1, KCNJ2, KCNB2 HTR2C 1162/4885HTR2A 1799/4885HTR2B 464/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.